A trip down memory lane (while we still have memories)

By the early 1990s, it was clear that hormone replacement therapy (HRT) — even the pharmaceutical version — made a meaningful difference to women's health and vitality during the years around menopause.

Questions remained about the long-term effects of HRT. Enter the Women's Health Initiative (WHI) in 1991 — a large-scale, long-term study of synthetic hormone use in women. In 2002, the study was stopped early, and the media ran wild with a particular headline. Close to 70% of women stopped taking their synthetic HRT practically overnight.

Here's the problem: the statistics from that announcement were widely misinterpreted for years. A pattern in data does not automatically mean a cause — and for a pattern to be meaningful, it needs to reach a certain level of confidence that it's NOT due to chance. That threshold was not met. Many of the statistical analyses from the WHI were misread, and the message that went out to the public did not match what the data actually showed.

As a 2017 review of the WHI put it: "highly unusual circumstances prevailed when the WHI trial was stopped. The investigators most capable of correcting the critical misinterpretations of the data were actively excluded from the writing and dissemination activities." The people who understood the numbers — and knew they were being interpreted incorrectly — were sidelined.

During all that time, many women suffered needlessly. They experienced changes in bone density, cognition, mood, vaginal comfort, and physical function — all of which affect quality of life and daily vitality. And they were told it was just something they'd have to accept.

Meanwhile, women have been using bioidentical estrogen, progesterone, testosterone, and DHEA successfully for decades. Studies exist — and while not as large as the WHI, they're robust enough to show that when used in balance and dosed appropriately, bioidentical hormone therapy has supported millions of women's long-term health and vitality.

What Makes A Good Headline?

Patients in the WHI study continued to be followed for additional years. No data emerged supporting the alarm that had driven the original headlines. That update did not make headlines — because bad news travels and good news doesn't. The media moved on. Women were still living without the benefits of hormone therapy, wondering why their doctors had taken them off it.

The NAMS Review 2.0 (in 2017)

In 2017, a formal review of the WHI was published — one that laid out exactly how the data had been mishandled and how the public record needed to be corrected. It was an important moment. And it set the stage for what came next.

Key Summary Points For 2022

In July 2022, the North American Menopause Society (NAMS) updated its position statement on hormone replacement. This was a significant update — twenty years of follow-up data, new research, and a more nuanced read of the evidence. Here are the key points worth knowing:

1. The WHI only examined oral synthetic estrogen and one synthetic progestogen. It did not look at bioidentical hormones, or at topical, pellet, or sublingual delivery — so its conclusions don't apply to those approaches.
2. Estrogen alone, without being balanced by progesterone, increases the risk of abnormal uterine bleeding and uterine lining changes. Balance matters.
3. Non-oral use of hormones — vaginal, transdermal — may offer advantages because the hormones bypass first-pass metabolism in the liver.
4. Micronized progesterone (bioidentical) behaves differently from synthetic progestogens. This distinction is clinically meaningful and is reflected throughout the NAMS review.
5. Low-dose vaginal estrogen has been discussed in clinical literature as an option for women experiencing vaginal dryness and related comfort concerns during menopause. According to the NAMS position statement, it is well-supported for this use. We encourage readers to review the full NAMS document and consult their healthcare provider.
6. Estrogen and progesterone therapy is approved for severe hot flashes, osteoporosis, very low estrogen levels, and vulvovaginal discomfort.
7. The belief that studies don't support bioidentical hormone replacement is contested. While studies may be smaller, there are significant studies that support its use. This remains, as NAMS acknowledges, a politically charged area. NAMS does not say "don't use bioidenticals" — but it does state that "patient preference alone should not be used to justify use of compounded bioidentical hormone therapy." Whether women get to choose for themselves is, as Kate would say, another can of worms entirely.
8. The NAMS position statement discusses estriol in the context of vaginal comfort for post-menopausal women. We encourage readers to review the full document and consult their healthcare provider to determine what's right for their individual situation.
9. Hormone delivery route matters for bladder and urinary comfort. Vaginal estrogen and oral synthetic hormone combinations have different profiles — a detail worth discussing with your provider.
10. Vaginal estrogen may be more effective than oral estrogen for libido and arousal. Oral estrogens can increase sex hormone binding globulin, which reduces the amount of free hormone available at receptor sites throughout the body.
11. Micronized progesterone is associated with reduced hot flashes and night sweats and may support better sleep.
12. Hormone therapy helps maintain bone density in healthy postmenopausal women. Given that we always want our bones strong — this finding suggests that long-term hormone use may be a genuinely good idea for many women.
13. The NAMS review noted potential associations between hormone therapy and metabolic markers, including blood sugar regulation. Readers interested in this area should discuss it with their healthcare provider.
14. Micronized progesterone appears more protective of the cardiovascular system than synthetic progestogens.
15. Hormone delivery route affects the risk profile for gallstones. Transdermal hormone therapy has a lower associated risk than oral synthetic estrogen combinations.
16. Oral synthetic hormone combinations are associated with increased risk of dementia — while there is no mention in the NAMS statement of bioidentical hormones' potential protective effects on the brain. That omission is frustrating, and we hope it's addressed in future updates.
17. Lifestyle factors are the biggest influences on long-term health risk. High inflammation, low activity, excess weight, smoking, and alcohol all compound one another. The effect of hormone therapy on long-term health risk may depend on hormone type, delivery method, duration of use, and individual characteristics — which is exactly why personalized, provider-guided care matters.
18. The overall message from the Menopause Society still leans toward synthetic hormone replacement used for a limited period. It does not fully reconcile all the long-term benefits that hormone therapy — particularly bioidentical — can provide with the decision to stop it. Women can live into their 90s. Cutting them off from hormones at 65 or 70 still leaves decades of potential benefit on the table.

Questions, Answers & More Questions…

In November 2025, the FDA removed a long-standing warning that had discouraged so many women from exploring hormone therapy options — including low-dose vaginal estrogen. The Menopause Society supported that decision.

Throughout the progression of updates from the Menopause Society, the thread of the message still seems focused on synthetic hormone replacement. Only passing reference is made to topical bioidentical hormones. We're hoping it won't take another twenty years for the full picture to be recognized — and for women to get the care they deserve.

This article is for educational and general wellness purposes only. It is not medical advice and is not intended to diagnose, treat, cure, or prevent any disease. If you are noticing changes in your body or have questions about your health, please consult a knowledgeable healthcare provider.